Suppr超能文献

由三甲基壳聚糖和岩藻聚糖自组装而成的多功能纳米粒子的开发用于增强胰岛素的口服递送。

Development of mutlifunctional nanoparticles self-assembled from trimethyl chitosan and fucoidan for enhanced oral delivery of insulin.

机构信息

Institute of Organic and Polymeric Materials, National Taipei University of Technology, Taipei 10608, Taiwan.

School of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.

出版信息

Int J Biol Macromol. 2019 Apr 1;126:141-150. doi: 10.1016/j.ijbiomac.2018.12.182. Epub 2018 Dec 23.

Abstract

Oral administration is a highly attractive approach for the delivery of protein drugs. However, oral protein therapeutics typically exhibit extremely poor bioavailability due to the harsh gastrointestinal (GI) environments and low permeability of protein across the intestinal barrier. Trimethyl chitosan (TMC) shows excellent mucoadhesive and absorption-enhancing properties while fucoidan (FD) has hypoglycemic effects and can prevent diabetes-related complications. Here we report, for the first time, that TMC combined with FD can be developed to a mutlifunctional nanoplatform for enhancing the transepithelial permeation of insulin through the intestinal epithelial cell barrier and inhibiting the α-glucosidase activity. TMC and FD self-assembled into spherical nanoparticles (NPs) for insulin encapsulation. TMC/FD NPs protected insulin against degradation by releasing insulin in a pH-dependent manner in the gastrointestinal tract fluids. The NPs were able to modulate the barrier function of the Caco-2 intestinal epithelial cell monolayer, and enhance paracellular transport of insulin across the intestinal barrier. TMC/FD NPs also showed α-glucosidase inhibitory activity, with an inhibition ratio of 33.2% at 2 mg/mL. The superior transepithelial absorption enhancing property of the TMC/FD NPs is expected to combine in the future with the functions of fucoidan against diabetes-related complications for development of advanced mutlifunctional therapeutic platforms for diabetes.

摘要

口服给药是一种极具吸引力的蛋白质药物递送方法。然而,由于胃肠道(GI)环境恶劣以及蛋白质穿过肠道屏障的通透性低,口服蛋白质治疗药物通常表现出极差的生物利用度。三甲基壳聚糖(TMC)具有极好的黏膜黏附性和吸收增强特性,而褐藻糖胶(FD)具有降血糖作用,可以预防糖尿病相关并发症。在这里,我们首次报道,TMC 与 FD 联合可以开发成多功能纳米平台,通过肠上皮细胞屏障增强胰岛素的跨上皮渗透并抑制α-葡萄糖苷酶活性。TMC 和 FD 自组装成球形纳米颗粒(NPs)用于包裹胰岛素。TMC/FD NPs 通过在胃肠道液中以 pH 依赖性方式释放胰岛素来保护胰岛素免受降解。这些 NPs 能够调节 Caco-2 肠上皮细胞单层的屏障功能,并增强胰岛素的跨肠道屏障的旁细胞转运。TMC/FD NPs 还表现出α-葡萄糖苷酶抑制活性,在 2mg/mL 时抑制率为 33.2%。TMC/FD NPs 的优越的跨上皮吸收增强特性有望与褐藻糖胶对糖尿病相关并发症的功能相结合,为糖尿病开发先进的多功能治疗平台。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验